MASCT by Hengrui Yuanzheng Biotechnology for Kidney Cancer (Renal Cell Cancer): Likelihood of Approval

MASCT is under clinical development by Hengrui Yuanzheng Biotechnology and currently in Phase I for Kidney Cancer (Renal Cell Cancer).

Health Commons Project Acquires OneHealthPort – M&A

What You Should Know: – Health Commons Project, a non-profit dedicated to improving healthcare access and quality, has acquired OneHealthPort, Washington State’s Health Information Exchange

November 8, 2024

Opinion | ‘This Medication Is Not the Panacea’: What We Heard This Week

“This medication is not the panacea to tackle the maternal mental health crisis.” — Judite Blanc, PhD, of the University of Miami Miller School of

August 14, 2023

MedPAC Draft Recommendation Calls for 1.3% Pay Bump for Medicare Clinicians

Physicians who treat Medicare patients would get about a 1.3% pay increase in 2025 under a draft chairman’s recommendation released Thursday by the Medicare Payment

December 8, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.